Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
Date:11/1/2010

SEATTLE, Nov. 1, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). The application submission follows a positive opinion from the EMA's Pediatric Committee (the "PDCO"), where PDCO agreed to CTI's Pediatric Investigation Plan ("PIP") for Pixuvri.

"This is an important milestone for CTI, and underscores our commitment to making pixantrone available to patients who currently have no approved or effective therapies for this life threatening disease," said James A. Bianco, M.D., CEO of CTI. "We appreciate the efforts of all the people who made the MAA submission possible, especially the investigators and patients who participated in our clinical trial."  

"PIX301 was not only the first and only randomized trial in this patient population, it was also the largest study ever conducted for patients with multiply relapsed and refractory aggressive NHL. The positive results of this trial are among the most effective ever reported in this group of patients," noted Ruth Pettengell, M.D., of St. George's Hospital, University of London, the principal investigator on the study. "The robustness of the drug's effect in prolonging progression free survival irrespective of risk factors lends to the strength and credibility of the clinical benefit provided to patients in the trial. Currently there are no approved drugs available to patients today as such pixantrone will be a valuable new addition to offer these patients a new hope for controlling their disease."

Pixantrone was granted orphan drug status by the EMA for the treatment of diffuse large B-cell lymphoma (DLBCL). CTI expects that the EMA will make a determination regarding the ac
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... DUBLIN and RALEIGH, N.C. ... subsidiary of Endo International plc (NASDAQ: ENDP ... BDSI ) announced today that they have ... Buccal Film to the U.S. Food and Drug Administration ... the management of pain severe enough to require daily, ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... "US Self-monitoring Blood Glucose Market" report to ... This market insight focuses on the developments ... the United States . Reimbursement analysis and the ... analyses for more than 73 SMBG meters have been ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
...   Syndax Pharmaceuticals, Inc ., a clinical-stage epigenetics oncology ... 2 clinical trials with entinostat in combination and as ... conferences.  San Antonio Breast Cancer ... randomized, double-blind, placebo-controlled, phase 2 study of exemestane with ...
...  Henry Schein, Inc., (NASDAQ: HSIC ), the ... office-based practitioners, announced today that Stanley Bergman, Chairman and ... the Company,s Executive Vice President and Chief Financial Officer, ... on December 6.  The conference is being held at ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Henry Schein to Present at the NASDAQ OMX 27th Investor Program 2
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... ... season, FORT WORTH, Texas, Nov. 13 ... Jude,during the 2008 holiday shopping season for the 5th anniversary of the,Thanks and ... RadioShack is asking customers to "Give thanks,for the healthy kids in your life, ...
... to emphasize smoking prevention for young girls has been ... Medical School (DMS). The safe, online patient education site ... prevent smoking in young girls 8-11 years old). , ... the siteNo Smoking Room.Org ( www.nosmokingroom.org ) is designed ...
... Nov. 13 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that Arthur Rudolph, its Founder,and a member of ... plan to sell a portion of his NBTY stock ... asset diversification and liquidity. The stock,trading plan was adopted ...
... (Nasdaq: AMLN ) will be presenting at the ... November,19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, ... providing a corporate overview., The live presentation will ... following the event. The Web cast and recording will ...
... $3.8 million Innovator Award, from the Department of Defense, ... renowned cancer researcher at the University of California, Santa ... is known for his innovative, interdisciplinary research. "This is ... them," said Ruoslahti. "I am very happy at being ...
... Nov. 13 Debiopharm Group,(Debiopharm), a global ... conditions and particularly oncology, today,announced that the ... month formulation,of Trelstar(R) (triptorelin pamoate) has been ... Food and Drug Administration (FDA). Trelstar(R) is ...
Cached Medicine News:Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 3Health News:Innovative new Web site empowers young girls to live smoke-free 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2Health News:Cancer researcher receives $3.8 million award from US Department of Defense 2Health News:Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer 2
DCR Set, Angled....
... The Leica CM3050 S Cryostat ... with excellent safety standards for ... applications. The Leica CM3050 S ... for all cryosectioning research applications ...
... The Bright 7500 is a freestanding ... liquid decontamination system and a radial ... to cut a wide range of ... effective for use in high biohazard ...
... - a vision becomes reality. Numerous ... the users many benefits.,The Cryo-Star is ... retraction that incorporates a unique refrigeration ... cooling. This facilitates applications in both ...
Medicine Products: